For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Ovid Therapeutics Inc (NASDAQ: OVID) closed at $1.58 in the last session, down -5.39% from day before closing price of $1.67. In other words, the price has decreased by -$5.39 from its previous closing price. On the day, 2.02 million shares were traded. OVID stock price reached its highest trading level at $1.67 during the session, while it also had its lowest trading level at $1.57.
Ratios:
We take a closer look at OVID’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.72 and its Current Ratio is at 4.72. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
On April 30, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $9.B. Riley Securities initiated its Buy rating on April 30, 2024, with a $9 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 26 ’25 when ALEXANDER MARGARET A. sold 5,279 shares for $0.56 per share. The transaction valued at 2,956 led to the insider holds 73,406 shares of the business.
Rona Jeffrey A sold 3,902 shares of OVID for $2,185 on Feb 26 ’25. The CBFO now owns 67,973 shares after completing the transaction at $0.56 per share. On Jan 27 ’25, another insider, ALEXANDER MARGARET A., who serves as the President and COO of the company, bought 6,810 shares for $0.73 each. As a result, the insider paid 4,971 and bolstered with 34,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OVID now has a Market Capitalization of 112353032 and an Enterprise Value of 88105032. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.89 while its Price-to-Book (P/B) ratio in mrq is 2.01. Its current Enterprise Value per Revenue stands at 13.247 whereas that against EBITDA is -2.138.
Stock Price History:
The Beta on a monthly basis for OVID is 0.30, which has changed by 0.44954133 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, OVID has reached a high of $2.01, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 41.65%, while the 200-Day Moving Average is calculated to be 145.49%.
Shares Statistics:
According to the various share statistics, OVID traded on average about 3.03M shares per day over the past 3-months and 8913250 shares per day over the past 10 days. A total of 71.11M shares are outstanding, with a floating share count of 59.52M. Insiders hold about 16.29% of the company’s shares, while institutions hold 35.28% stake in the company. Shares short for OVID as of 1757894400 were 488729 with a Short Ratio of 0.16, compared to 1755216000 on 1511017. Therefore, it implies a Short% of Shares Outstanding of 488729 and a Short% of Float of 0.8200000000000001.
Earnings Estimates
. The current rating of Ovid Therapeutics Inc (OVID) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.42 and -$0.46 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.38, with 4.0 analysts recommending between -$0.22 and -$0.59.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for OVID’s current fiscal year. The highest revenue estimate was $7.39M, while the lowest revenue estimate was $6.4M, resulting in an average revenue estimate of $6.7M. In the same quarter a year ago, actual revenue was $566k
